Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 24;32(10):684.
doi: 10.1007/s00520-024-08868-7.

Learning about and living with toxicity: a qualitative study of patients receiving immune checkpoint inhibitors for melanoma or lung cancer and their caregivers

Ayo S Falade  1   2 , Mary C Boulanger  3 , Kelly Hsu  4 , Roshni Sarathy  5 , Riley Fadden  3 , Kerry L Reynolds  3 , Lara Traeger  6   7 , Jennifer S Temel  3 , Joseph A Greer  6 , Laura A Petrillo  8
Affiliations

Learning about and living with toxicity: a qualitative study of patients receiving immune checkpoint inhibitors for melanoma or lung cancer and their caregivers

Ayo S Falade et al. Support Care Cancer. .

Abstract

Background/objective: Immune checkpoint inhibitors (ICIs) have revolutionized treatment for melanoma and lung cancer and are in widespread use. This study aims to describe how patients and caregivers learn about ICI toxicities and their perceptions and experiences of toxicity.

Methods: We conducted a qualitative study of 42 patients with advanced non-small cell lung cancer (NSCLC; n = 16) or melanoma (n = 26) who were initiating or discontinuing an ICI and their caregivers (n = 9). We conducted in-depth interviews to explore patients' and caregivers' experiences learning about and living with ICI side effects. We audio-recorded the first oncology visit after enrollment. We used a framework approach to code interview and visit transcripts and synthesized codes into themes.

Results: The median age of patients was 67; 68% were male. Themes of participant interviews and clinician-patient dialogue included: (i) Patients initiating an ICI received extensive information about side effects, which some patients found overwhelming or scary and difficult to absorb; (ii) patients who were deterred by fear of toxicity ultimately proceeded with treatment because of oncologist encouragement or the sense of no alternative; (iii) participants found hope in the association between toxicity and ICI efficacy; (iv) caregivers helped patients navigate the deluge of information and uncertainty related to ICIs. Participants suggested ways to improve ICI side effect education, such as incorporating patient stories.

Conclusion: Patients perceived that ICI toxicity counseling was overwhelming yet were encouraged by oncologists' reassurance that serious side effects were manageable and by the framing of toxicity as a sign of efficacy. We identified opportunities to improve communication of ICI risks and benefits.

Keywords: Caregivers' perspectives; Communication; Humanistic medicine; Immune-related adverse events; Patients' perspectives.

PubMed Disclaimer

References

    1. FDA approves first immunotherapy treatment for lung cancer - NCI [Internet] (2015) Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2015/fda-opdivo . Accessed 3 Jan 2023
    1. Onoi K, Chihara Y, Uchino J, Shimamoto T, Morimoto Y, Iwasaku M et al (2020) Immune checkpoint inhibitors for lung cancer treatment: a review. J Clin Med 9(5):1362 - PubMed - PMC
    1. Lamba N, Ott PA, Iorgulescu JB (2022) Use of first-line immune checkpoint inhibitors and association with overall survival among patients with metastatic melanoma in the anti–PD-1 era. JAMA Netw Open 5(8):e2225459 - PubMed - PMC
    1. Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L et al (2019) Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res Off J Am Assoc Cancer Res 25(15):4592–4602
    1. Weiss SA, Wolchok JD, Sznol M (2019) Immunotherapy of melanoma: facts and hopes. Clin Cancer Res 25(17):5191–5201 - PubMed - PMC

Substances

LinkOut - more resources